Related Experiment Video
Updated: Mar 19, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Genitourinary cancers: molecular determinants for personalized therapies
Roberta Mazzucchelli1, Silvia Gasparrini1, Andrea B Galosi2
1Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona - Italy.
Precision medicine utilizes genomic and molecular profiles for individualized genitourinary (GU) cancer therapy. Advances in sequencing technologies enable tailored treatments based on unique patient and tumor characteristics.
Area of Science:
- Oncology and Genomics
- Molecular Biology and Bioinformatics
Background:
- Genitourinary (GU) cancers require personalized treatment strategies.
- Genomic and molecular profiling are crucial for effective therapy.
Discussion:
- Next-generation sequencing and whole-exome sequencing have significantly advanced cancer research.
- These technologies reveal complex genomic abnormalities in cancer cells.
- This knowledge underpins the development of precision medicine.
Key Insights:
- Individualized therapeutic approaches for GU cancers are driven by genomic and molecular data.
- Novel sequencing technologies enhance understanding of cancer cell biology.
- Precision medicine offers a personalized healthcare perspective for GU tumor patients.
Outlook:
- Continued advancements in sequencing will further refine precision oncology.
- Integration of multi-omics data will deepen insights into GU cancer development.
- Personalized treatment strategies promise improved outcomes for GU cancer patients.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

